Table 3.
Patient outcomes prior to telehealth and during telehealth incorporation into gynecologic oncology therapeutic clinical trials.
Lab = Laboratory, ED = Emergency Department, AE = adverse event SAE = severe adverse event
* Utilizing Common Terminology Criteria for Adverse Events
P-values are listed for t-test, with non-parametric Wilcoxon signed-rank listed when differed in significance.
| Pre-Telehealth | Telehealth | Patient ttest p- value |
Rate ttest p- value |
|||||
|---|---|---|---|---|---|---|---|---|
| Count | Per Patient |
Rate | Count | Per Patient |
Rate | |||
| Extra Provider Visit | 31 | 1.0 (0-10) | 0.31 (0-3.10) | 29 | 0.94 (0-5) | 0.25 (0-1.90) | 0.837 | 0.475 |
| Patient Touchpoints | 149 | 4.81 (0-22) | 1.31 (0-7.67) | 202 | 6.52 (0-22) | 1.50 (0-6.08) | 0.126 | 0.477 |
| Extra Lab Testing | 13 | 0.42 (0-4) | 0.09 (0-0.77) | 31 | 1.0 (0-8) | 0.22 (0-1.56) | 0.161 | 0.139 |
| Extra Imaging | 6 | 0.19 (0-1) | 0.05 (0-0.64) | 22 | 0.71 (0-3) | 0.17 (0-0.71) | 0.003 | 0.010 |
| Treatment Reduction | 4 | 0.13 (0-1) | 0.03 (0-0.27) | 9 | 0.29 (0-2) | 0.09 (0-1.0) | 0.169 | 0.089 |
| Treatment Delay | 10 | 0.32 (0-2) | 0.07 (0-0.64) | 13 | 0.42 (0-2) | 0.11 (0-1.0) | 0.476 | 0.407 |
| Total AE* | 321 | 10.35 (1-24) | 3.32 (0.18-15) | 285 | 9.19 (0-35) | 2.12 (0-9) | 0.302 | 0.046 |
| Total SAE (Grade 3 or higher)* | 19 | 0.61 (0-4) | 0.33 (0-5) | 19 | 0.61 (0-3) | 0.12 (0-0.54) | 0.999 | 0.187 |
| ED Visits | 4 | 0.13 (0-2) | 0.03 (0-0.70) | 6 | 0.19 (0-2) | 0.04 (0-0.44) | 0.625 | 0.915 |
| Hospital Admissions | 2 | 0.06 (0-2) | 0.01 (0-0.36) | 5 | 0.16 (0-2) | 0.03 (0-0.36) | 0.374 | 0.349 |
| Transfusion/Infusion Visits | 13 | 0.42 (0-8) | 0.08 (0-1.44) | 16 | 0.52 (0-8) | 0.10 (0-1.44) | 0.557 | 0.572 |